This included the technology ProFound AI for Digital Breast Tomosynthesis (DBT), which is said to be the first artificial intelligence software for DBT to be approved by the U.S. Food and Drug Administration (FDA). Also on offer at the event were medical software solutions designed for 2D mammography and to assess breast density. During the meeting, the iCAD unveiled its vision for future technologies. This predictive aspect included technologies that should enable clinicians to more easily interpret patients' earlier images and prospective breast cancer risk assessment to form a clearer picture of the specific patient's condition. Clinical data from a large reader study involving ProFound AI for DBT were recently published in the journal Radiology: Artificial Intelligence ("Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis").